Shanghai Henlius Biotech, Inc. (FRA:2E8)

Market Cap	4.06B -18.1%
Revenue (ttm)	958.09M +28.2%
Net Income	111.76M +5.2%
EPS	0.20 +4.1%
Shares Out	n/a
PE Ratio	36.31
Forward PE	36.27
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63
Open	7.40
Previous Close	7.25
Day's Range	7.40 - 7.70
52-Week Range	5.70 - 9.05
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s diseas...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 3,762
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2E8

Financial Performance

In 2025, Shanghai Henlius Biotech's revenue was 6.67 billion, an increase of 16.46% compared to the previous year's 5.72 billion. Earnings were 827.04 million, an increase of 0.80%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error